A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

7.6K views

⸱

DOI:

10.3791/50865

⸱

January 14th, 2014

 ,  ,  , 

In This Article

Summary

Malignant gliomas constitute a heterogeneous group of highly infiltrative glial neoplasms with distinct clinical and molecular features. Primary orthotopic xenografts recapitulate the histopathological and molecular features of malignant glioma subtypes in preclinical animal models.

Abstract

Malignant gliomas constitute a heterogeneous group of highly infiltrative glial neoplasms with distinct clinical and molecular features. Primary orthotopic xenografts recapitulate the histopathological and molecular features of malignant glioma subtypes in preclinical animal models. To model WHO grades III and IV malignant gliomas in transplantation assays, human tumor cells are xenografted into an orthotopic site, the brain, of immunocompromised mice. In contrast to secondary xenografts that utilize cultured tumor cells, human glioma cells are dissociated from resected specimens and transplanted without prior passage in tissue culture to generate primary xenografts. The procedure in this report details tumor sample preparation, intracranial transplantation into immunocompromised mice, monitoring for tumor engraftment and tumor harvesting for subsequent passage into recipient animals or analysis. Tumor cell preparation requires 2 hr and surgical procedure requires 20 min/animal.

Introduction

Malignant gliomas are primary glial tumors of the central nervous system that occur in the brain and occasionally the spinal cord. Gliomas are classified by the World Health Organization (WHO) according to histologic resemblance to astrocytes, oligodendrocytes or ependymal cells and then numerically graded (I to IV) for pathologic features of malignancy. The most common histologic subtypes are astrocytomas, oligodendrogliomas and mixed oligoastrocytomas. Malignant gliomas encompassing WHO grades II to IV are characterized by invasive growth and recalcitrance to current therapies. Each year in the United States, approximately 15,750 individuals are diagnosed with a mal....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Preparation of Tumor Cell Suspension

Note: Appropriate institutional approvals for the use of patient material and animals are required to establish and maintain primary orthotopic glioma xenografts. At Vanderbilt University Medical Center, resected tumor material that is in excess of that required for diagnostic purposes is collected with patient consent for a research tissue repository. Specimens are labeled with a randomized 5-digit REDcap database number and all patient-specific identifiers are removed. The REDcap database contains deidentified clinical data for each specimen in the tissue repository that includes gen....

Access restricted. Please log in or start a trial to view this content.

Results

Dissociated glioma cells are transplanted directly into the brains of immunocompromised mice to obtain primary orthotopic xenograft lines. Each tumor specimen is assigned a randomized number prior to transplantation, as part of the deidentification process to remove protected health information. We use a 5-digit REDcap database number for this purpose. Figure 1 illustrates the process and nomenclature for establishing a xenograft line from a glioblastoma (GBM 17182) with isocitrate dehydrogenase 1 (IDH1).......

Access restricted. Please log in or start a trial to view this content.

Discussion

Cultured cell lines, xenografts and genetically engineered mice are the most common methods for modeling gliomas, and there are distinct benefits and limitations for each model system3,13,14. Relevant benefits of primary orthotopic glioma xenografts include infiltrative growth that typifies diffuse gliomas and the retention of genetic alterations and important signaling mechanisms that can be exceedingly difficult to maintain in cultured glioma cells. For example, isocitrate dehydrogenase mutations an.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

We are particularly indebted to patients at Vanderbilt University Medical Center who provided invaluable research material for the Molecular Neurosurgical Tissue Bank. We thank those who established and maintain the Tissue Bank, Reid C. Thompson MD (principal investigator), Cherryl Kinnard RN (research nurse) and Larry A. Pierce MS (manager). Histological services were performed, in part, by the Vanderbilt University Medical Center (VUMC) Translational Pathology Shared Resource (supported by award 5P30 CA068485 to the Vanderbilt-Ingram Cancer Center). This work was supported by grants to MKC from the NINDS (1R21NS070139), the Burroughs Wellcome Fund and VMC developmen....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Phosphate buffered salineLife Technologies14040-133
Papain dissociation systemWorthington Biochemical Corp.LK003150
Trypan blue solution 0.4%Life Technologies15250061
Ketamine HClObtained from institutional pharmacy or local veterinary supply company
Xylazine HCl
Ketoprofen

Ophthalmic ointment

Povidone-iodine

Fisher Scientific

190061617

Cryopreservation medium and proliferation supplement

StemCell Technologies

05751

0.2% Heparin sodium salt in PBS

StemCell Technologies

07980

Penicillin-streptomycin

Life Technologies

15140-122

Dimethyl sulfoxide

Sigma-Aldrich

D6250-5X10ML

NOD.Cg-Prkdcscid I/2rgtm1Wjl/SzJ mice

The Jackson Laboratory

005557

NSG mice

Anti-human vimentin antibody

Dako

M7020

Use 1:200 to 1:800

Anti-human IDH1 R132H antibody

Dianova

DIA-H09

Use 1:100 to 1:400

Centrifuge with swinging bucket rotor

Pipetter with dispensing speed control

Disposable hemocytometer

Fisher Scientific

22-600-100

Sterile surgical gloves

Fisher Scientific

11-388128

Disposable gown

Fisher Scientific

18-567

Surgical mask

Fisher Scientific

19-120-1256

Tuberculin syringe

BD

305620

Alcohol pads

Fisher Scientific

22-246-073

Portable electronic scale

Fisher Scientific

01-919-33

Zoom stereomicroscope

Surgical clipper

Stoelting

51465

Scalpel handle

Fine Science Tools

10003-12

Scalpel blades, #10

Stereotaxic instrument

Stoelting

51730

High-speed drill

Stoelting

51449

Drill bit, 0.6 mmStoelting514552

Hamilton syringe

Hamilton

80336

Autoclip, 9 mm

BD

427630

Circulating water warming pad

Kent Scientific

TP-700

TP-1215EA

Hot bead dry sterilizer

Kent Scientific

INS300850

Surgical scissors

Fine Science Tools

14101-14

Fine scissors

Fine Science Tools

14094-11

Spring scissors

Fine Science Tools

15018-10

Dumont forceps

Fine Science Tools

11251-30

Semimicro spatulas

Fisher Scientific

14374

Mouse brain slicer matrix

Zivic Instruments

BSMAS002-1

Cryogenic storage vials

Fisher Scientific

12-567-501

References

  1. Johnson, J. I., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. 84, 1424-1431 (2001).
  2. Witt Hamer, D. e, C, P., et al.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Primary Orthotopic XenograftsGlioma Cell SuspensionIntracranial TransplantationImmunocompromised MiceTumor Engraftment MonitoringHistology AnalysisDNA SequencingIDH Mutation RetentionPepane DissociationFlow Cytometry Analysis